Industry
Biotechnology
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 10:40 am
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 11:23 am
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 11:21 am
Portfolio Pulse from Benzinga Insights
June 28, 2024 | 4:01 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 10:12 am
Portfolio Pulse from Avi Kapoor
June 24, 2024 | 7:32 am
Portfolio Pulse from Benzinga Newsdesk
June 21, 2024 | 8:09 pm
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 2:19 pm
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 2:32 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.